Printer Friendly

CELLEX BIOSCIENCES ENTERS INTO DISTRIBUTION AGREEMENT WITH RECEPTOR TECHNOLOGIES LIMITED OF ENGLAND

 MINNEAPOLIS, July 27 /PRNewswire/ -- Cellex Biosciences, Inc. (NASDAQ: CLXX) announced today that it has entered into a distribution agreement with Receptor Technologies Limited, a cell culture product distribution company located in Oxon, England. Receptor Technologies will market, in England and Ireland, the product line recently acquired from Verax Corporation by Cellex Biosciences in May 1993. The Verax technology utilizes a fluidized bed cell culture technology that has proven to be effective for the growth of certain types of cells including monoclonal antibodies and recombinant proteins.
 Richard E. Sakowicz, Cellex Biosciences, Inc. president and chief operating officer, said, "We are very pleased to have Receptor Technologies as our distribution partner for the Verax product line. Receptor Technologies has a long and extensive list of contacts with most of the users of bioreactors throughout the U.K. and good contacts with most of the opinion leaders within the industry and academia. This agreement will bring us one step closer to strengthening our international sales. Receptor Technologies, which distributed for the Verax Corporation for two years, will continue sales activities with focused effort on placing the benchtop System One(TM) and System 20(TM) into key pharmaceutical and biotechnology companies throughout the U.K."
 Cellex Biosciences, Inc., headquartered in Minneapolis, is dedicated to providing cell processing products and services to meet the needs of human health care and biotechnology markets worldwide.
 -0- 7/27/93
 /CONTACT: Yvonne L. Marschner-Bova, director, Investor Relations, Cellex Biosciences, 313-871-7350/
 (CLXX)


CO: Cellex Biosciences, Inc.; Receptor Technologies Limited ST: Minnesota IN: MTC SU:

ML -- DE003 -- 6040 07/27/93 08:12 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1993
Words:264
Previous Article:STARTING A PAINTING PROJECT: WHICH BRUSH IS BEST?
Next Article:VASCULAR TESTING INDUSTRY UNITES TO FORM THE ASSOCIATION FOR COST-EFFECTIVE CARDIOVASCULAR TECHNOLOGY
Topics:


Related Articles
CELLEX BIOSCIENCES TRANSFERS BIO-ARTIFICIAL LIVER PROJECT TO REGENEREX
CELLEX BIOSCIENCES, INC. ENTERS INTO DISTRIBUTION AGREEMENT WITH SCI-MEDIA, LTD. OF JAPAN
CELLEX BIOSCIENCES, INC. REPORTS FOURTH QUARTER AND FISCAL 1993 YEAR END RESULTS
CELLEX BIOSCIENCES FINALIZES ACQUISITION AGREEMENT WITH LSL GROUP, LTD.
CELLEX BIOSCIENCES INC. HOLDS ANNUAL MEETING OF SHAREHOLDERS: UPDATES INVESTMENT COMMUNITY ON RECENT DEVELOPMENTS
CELLEX BIOSCIENCES SELECTS GHBM MIDWEST AS MARKETING AGENCY
CELLEX BIOSCIENCES RECEIVES FIVE-YEAR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH TO CONTINUE NATIONAL CELL CULTURE CENTER
CELLEX BIOSCIENCES SUBSIDIARY LSL BIOLAFITTE OBTAINS THAILAND ORDER
CELLEX BIOSCIENCES ANNOUNCES 'CE' MARK CERTIFICATION
Cellex Biosciences and Unisyn Technologies Announce Intent to Merge, Merger Would Create First Fully Integrated Cell Culture Products and Services...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters